The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The Heart in Human Dystrophinopathies
Abstract
Dystrophinopathies are due to mutations in the dystrophin gene on chromosome Xp21.1 and comprise the allelic entities Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilative cardiomyopathy (XLDCM). In all three entities, the heart is affected to various degrees, depending on the stage of the disease and the type of the mutation (cardiac involvement, CI). The pathoanatomic evidence of CI in dystrophinopathies is the replacement of myocardium by connective tissue or fat. In DMD/BMD, the left ventricular posterobasal and lateral walls are most extensively affected, sparing the right ventricle and the atrium. Degree and dynamics of CI vary among the three entities. In DMD/BMD, CI usually remains subclinical in the early stages of the disease. Typical initial manifestations of CI in DMD/BMD are sinus tachycardia, tall R1 in V1, prominent Q in I, aVL, V6 or in II, III, and aVF, increased QT dispersion and possibly autonomic dysfunction. Initially, echocardiography is normal or shows regional wall motion abnormalities in areas of fibrosis. With spreading of fibrosis, left ventricular dysfunction and ventricular arrhythmias additionally occur. In the final stages of the disease, systolic function may lead to heart failure and sudden death. Subclinical or clinical CI is present in about 90% of the DMD/BMD patients but is the cause of death in only 20% of the DMD and 50% of the BMD patients. XLDCM is a rapidly progressive, almost exclusively myocardial disorder, starting in teenage males as heart failure due to dilative cardiomyopathy (CMP), leading to death from intractable heart failure within 1–2 years after diagnosis. Therapy of arrhythmias and CMP in all three disorders follows the established cardiological recommendations. Due to its protective effect, ACE inhibitors are recommended already at the early stages of the disease. β-Blockers may be an additional option if indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Gregoratos, G., Abrams, J., Epstein, A. E., Freedman, R. A., Hayes, D. L., Hlatky, M. A., Kerber, R. E., Naccarelli, G. V., Schoenfeld, M. H., Silka, M. J., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02528-7 · Cited by 1,266
The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy
Nigro, G., Comi, L. I., Politano, L., & Bain, R. J. I. (1990) · International Journal of Cardiology · doi:10.1016/0167-5273(90)90082-g · Cited by 731
(1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00024-2 · Cited by 632
Towbin, J. A., Hejtmancik, J. F., Brink, P., Gelb, B., Zhu, X. M., Chamberlain, J. S., McCabe, E. R., & Swift, M. (1993) · Circulation · doi:10.1161/01.cir.87.6.1854 · Cited by 516
Deletion of the Dystrophin Muscle-Promoter Region Associated with X-Linked Dilated Cardiomyopathy
Muntoni, F., Cau, M., Ganau, A., Congiu, R., Arvedi, G., Mateddu, A., Marrosu, M. G., Cianchetti, C., Realdi, G., Cao, A., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309233291304 · Cited by 416
Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Florence, J., King, W. M., Pandya, S., Robison, J., Schierbecker, J., et al. (1989) · Neurology · doi:10.1212/wnl.39.4.475 · Cited by 353
Bushby, K., Muntoni, F., & Bourke, J. P. (2003) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00213-4 · Cited by 300
The pathology of the heart in progressive muscular dystrophy: Epimyocardial fibrosis
Frankel, K. A., & Rosser, R. J. (1976) · Human Pathology · doi:10.1016/s0046-8177(76)80053-6 · Cited by 287
The role of cytoskeletal proteins in cardiomyopathies
Towbin, J. A. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80096-3 · Cited by 273
Cited by
Respiratory Care of the Patient with Duchenne Muscular Dystrophy: ATS Consensus Statement
(2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-885st · Cited by 733
Myofibroblast-mediated mechanisms of pathological remodelling of the heart
Weber, K. T., Sun, Y., Bhattacharya, S. K., Ahokas, R. A., & Gerling, I. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.158 · Cited by 673
The Dystrophin Glycoprotein Complex: Signaling Strength and Integrity for the Sarcolemma
Lapidos, K. A., Kakkar, R., & McNally, E. M. (2004) · Circulation Research · doi:10.1161/01.res.0000126574.61061.25 · Cited by 524
TGF-β Family Signaling in Tumor Suppression and Cancer Progression
Seoane, J., & Gomis, R. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022277 · Cited by 510
Small and large animal models in cardiac contraction research: advantages and disadvantages
Milani-Nejad, N., & Janssen, P. M. L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.007 · Cited by 484
BEFFAGNA, G., OCCHI, G., NAVA, A., VITIELLO, L., DITADI, A., BASSO, C., BAUCE, B., CARRARO, G., THIENE, G., & TOWBIN, J. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.10.005 · Cited by 422
Mechanisms of Altered Ca 2+ Handling in Heart Failure
Luo, M., & Anderson, M. E. (2013) · Circulation Research · doi:10.1161/circresaha.113.301651 · Cited by 357
Kozakowska, M., Pietraszek-Gremplewicz, K., Jozkowicz, A., & Dulak, J. (2015) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-015-9438-9 · Cited by 331
Dystrophic heart failure blocked by membrane sealant poloxamer
Yasuda, S., Townsend, D., Michele, D. E., Favre, E. G., Day, S. M., & Metzger, J. M. (2005) · Nature · doi:10.1038/nature03844 · Cited by 313
Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings
Quinlan, J. G., Hahn, H. S., Wong, B. L., Lorenz, J. N., Wenisch, A. S., & Levin, L. S. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.04.007 · Cited by 281
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117
Delfín, D. A., Zang, K. E., Schill, K. E., Patel, N. T., Janssen, P. M. L., Raman, S. V., & Rafael-Fortney, J. A. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.05.002 · Cited by 27
“Ninety-five percent of Duchenne muscular dystrophy (DMD) patients develop cardiomyopathy due to a lack of dystrophin protein in the heart, and greater than 25% die from heart failure [1–3].”
Background
Metadata
- Authors
- Finsterer, J., & Stöllberger, C.
- Venue
- Cardiology
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 99
- Issue
- 1
- Pages
- 1-19
- ISSN
- 0008-6312 (ISSN-L)
- 1421-9751
- OpenAlex
- W2051741101
- Cited by
- 439
- References
- 60
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.